



Synlogic to Present at the 17th Annual Needham Healthcare Conference

March 21, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 21, 2018-- Synlogic([Nasdaq:SYBX](https://www.nasdaq.com/symbol/sybx)) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic's president and chief executive officer, will present a corporate update at the 17th Annual Needham Healthcare Conference at 12:15 p.m. ET on Wednesday, March 28, 2018, in New York City.

A live webcast of the presentation can be accessed under "[Event Calendar](#)" in the Investors & Media section of the Company's website. An archived webcast recording will be available on the Synlogic website for approximately 30 days after the event.

About Synlogic:

Synlogic is pioneering the development of a novel class of living treatments, Synthetic Biotic™ medicines, based on its proprietary drug development platform. Synlogic's initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180321006070/en/>

Source: Synlogic

Synlogic

MEDIA CONTACT:

Courtney Heath, 617-872-2462

courtney@scientpr.com

or

INVESTOR CONTACT:

Elizabeth Wolffe, Ph.D., 617-207-5509

liz@synlogictx.com